At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 24 enrolled
Drug / intervention
PF-06865571 100 mgdrug
Likely dose
PF-06865571 100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A PHASE 1, NON-RANDOMIZED, OPEN-LABEL, SINGLE-DOSE, PARALLEL-COHORT STUDY TO COMPARE THE PHARMACOKINETICS OF PF 06865571 IN ADULT PARTICIPANTS WITH VARYING DEGREES OF HEPATIC IMPAIRMENT RELATIVE TO PARTICIPANTS WITHOUT HEPATIC IMPAIRMENT
In Brief
A Phase 1 clinical trial evaluating PF-06865571 100 mg for Hepatic Impairment and Healthy Volunteers. Completed, enrolled 24 participants across 2 sites.
Detailed Summary
The current study is proposed to evaluate whether there is any clinically meaningful effect of hepatic impairment on the plasma PK of PF-06865571.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHepatic Impairment, Healthy Volunteers
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
2020202120222023202420252026
First PostedSep 2019
Enrollment StartOct 2019
Primary CompletionApr 2020
TodayJul 2026
First PostedSep 16, 2019
Enrollment StartOct 3, 2019
Primary CompletionApr 7, 2020
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 6.8 years ago
Interventions
PF-06865571 100 mgdrug
PF-06865571 in 100 mg oral tablet will be administered on Day 1